← All trials
NCT04982237
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2021
- Primary completion
- Apr 1, 2025
- Completion date
- Dec 30, 2025
- First posted
- Jul 29, 2021
- Last posted
- Jul 29, 2021
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.